Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8533039rdf:typepubmed:Citationlld:pubmed
pubmed-article:8533039lifeskim:mentionsumls-concept:C0027763lld:lifeskim
pubmed-article:8533039lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8533039lifeskim:mentionsumls-concept:C0024141lld:lifeskim
pubmed-article:8533039lifeskim:mentionsumls-concept:C0699748lld:lifeskim
pubmed-article:8533039lifeskim:mentionsumls-concept:C2699007lld:lifeskim
pubmed-article:8533039pubmed:issue5lld:pubmed
pubmed-article:8533039pubmed:dateCreated1996-2-1lld:pubmed
pubmed-article:8533039pubmed:abstractTextSeveral different pathogenic mechanisms appear to be involved in CNS lupus. These include: B-cell/autoantibody-mediated nervous system compromise; immune complex deposition and vasculitis; microthrombosis and vasculopathy; aberrant MHC Class II antigen expression with T-cell mediated disease (multiple-sclerosis model); and, cytokine-induced brain inflammation. These processes are not mutually exclusive: there exist in vitro and in vivo models for each of these. A number of autoantibodies, especially those with specificities for shared neuronal/lymphocyte antigens, are associated with certain forms of cognitive dysfunction or overt nervous system manifestations. In MRL/lpr mice, lymphoid infiltrates in the brain parenchyma are related to a neurobehavioural dysfunction which develops very early in the course of autoimmune disease. Recent results, both in animal models and in human studies on the therapeutic effects of corticosteroids, immunosuppressive drugs or anticoagulants on clinical and subclinical manifestations of CNS lupus are highlighted in an attempt to develop a rationale for intervention based upon presumed pathogenesis.lld:pubmed
pubmed-article:8533039pubmed:languageenglld:pubmed
pubmed-article:8533039pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8533039pubmed:citationSubsetIMlld:pubmed
pubmed-article:8533039pubmed:statusMEDLINElld:pubmed
pubmed-article:8533039pubmed:issn0300-9742lld:pubmed
pubmed-article:8533039pubmed:authorpubmed-author:SzechtmanHHlld:pubmed
pubmed-article:8533039pubmed:authorpubmed-author:CarbotteR MRMlld:pubmed
pubmed-article:8533039pubmed:authorpubmed-author:DenburgJ AJAlld:pubmed
pubmed-article:8533039pubmed:authorpubmed-author:Saki?BBlld:pubmed
pubmed-article:8533039pubmed:authorpubmed-author:DenburgS DSDlld:pubmed
pubmed-article:8533039pubmed:issnTypePrintlld:pubmed
pubmed-article:8533039pubmed:volume24lld:pubmed
pubmed-article:8533039pubmed:ownerNLMlld:pubmed
pubmed-article:8533039pubmed:authorsCompleteYlld:pubmed
pubmed-article:8533039pubmed:pagination263-73lld:pubmed
pubmed-article:8533039pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:meshHeadingpubmed-meshheading:8533039-...lld:pubmed
pubmed-article:8533039pubmed:year1995lld:pubmed
pubmed-article:8533039pubmed:articleTitleNervous system lupus: pathogenesis and rationale for therapy.lld:pubmed
pubmed-article:8533039pubmed:affiliationDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.lld:pubmed
pubmed-article:8533039pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8533039pubmed:publicationTypeReviewlld:pubmed
pubmed-article:8533039pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8533039lld:pubmed